A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

WHO’s Doing What?

Read time:
NCD Alliance

With the New Year underway, GHTC is looking forward to a busy spring of multilateral organization meetings—with a number of them impacting global health research and development (R&D). First on the agenda is the World Health Organization (WHO) Executive Board (EB) meeting on January 25–30 in Geneva, where the EB will receive updates on a number of topics and make important decisions, particularly around how to proceed with the next steps of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) process.

January 21, 2016 by Matthew Robinson

With the New Year underway, GHTC is looking forward to a busy spring of multilateral organization meetings—with a number of them impacting global health research and development (R&D). First on the agenda is the World Health Organization (WHO) Executive Board (EB) meeting on January 25–30 in Geneva, where the EB will receive updates on a number of topics and make important decisions, particularly around how to proceed with the next steps of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) process.

The full provisional agenda is available here, but below, GHTC’s Matt Robinson highlights what you can expect on global health R&D related topics.

10930778_881925875186130_5579280952004258258_o
WHO Executive Board (Photo: NCD Alliance)

Agenda item #7 – Promoting health through the life course – Tuesday, January 26

7.1 – Monitoring of the achievement of the health-related Millennium Development Goals (MDGs) – Update to the Board

The development of indicators to monitor progress toward the health-related MDGs has been a key priority for the WHO. This update to the Board outlines the current slate of health indicators, including indicator 8.E on affordable access to medicines.

7.2 – Health in the 2030 agenda for sustainable development – Update to the Board

In this session the WHO Secretariat will present a report tracing the development of the Sustainable Development Goals (SDGs), outlining key differences from the MDGs, and highlighting potential changes required at WHO to ensure a leading role for health in the new SDG framework. As the lead United Nations agency on health, how effectively WHO can continue to advocate for the role of health in achieving the broader SDGs will shape the global health landscape.

GHTC has been tracking progress on the SDG monitoring framework and proposed specific indicators to measure global health R&D in our report, “ Measuring Global Health R&D for the Post-2015 Development Agenda.” GHTC also produced a factsheet and a webinar on innovation in the SDGs.

Agenda item #8 – Preparedness, surveillance and response – Wednesday, January 27

8.5 – Global action plan on antimicrobial resistance – Update to the Board

Following on two previous World Health Assembly (WHA) resolutions on antimicrobial resistance, the Secretariat will propose either a summit at the opening of the 2016 General Assembly or a high-level side event on the margins of the same. Given the dramatic rise in antimicrobial resistance globally, WHO hopes to use this high-level event to mobilize global support and resources both to develop new antibiotics and to ensure that current drugs are used appropriately.

Agenda item #9 – Communicable diseases – Tuesday, January 26

9.1 – 2014 Ebola virus disease outbreak and issues raised: follow-up to the Special Session of the Executive Board on the Ebola Emergency (resolution EBSS3.R1) and the Sixty-eighth World Health Assembly (decision WHA68(10))

Unfortunately the text of this report is not yet available, stay tuned for our post-EB blog and more information!

Agenda item #10 – Health systems – Thursday, January 28

10.2 – Comprehensive evaluation of the global strategy and plan of action on public health, innovation and intellectual property: progress update – Update to the Board

The 2015 WHA directed the WHO Director-General to undertake an evaluation of the global strategy and plan of action on health, innovation, and intellectual property. The Secretariat will present a report outlining the work conducted so far, as well as an addendum containing key points from the evaluation inception report, including the principles that will be used in developing the full evaluation plan and design.

10.3 – Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination – Planning for an open-ended meeting of Member States to discuss progress – Board Decision

This report and decision point are two key items on the EB agenda. The CEWG on Research and Development: Financing and Coordination process continues moving forward and faces some key decisions in the coming months. At the meeting, the EB will decide if civil society will be able to participate consultative open-ended meetings scheduled for March, which will determine what resolution is put forward to the WHA. GHTC is a strong advocate for civil society’s inclusion in the process.

10.4 – Substandard/spurious/falsely-labelled/falsified/counterfeit medical products – Update to the Board

The Director-General of the WHO was directed to convene a series of expert consultations on possible methods to counteract substandard as well as falsified medical products by a 2012 WHA resolution. To that end, a number of expert committees have met and produced the priority recommendation of creating a global network of focal points to tackle issues in the quality of the drug supply. These focal points would then be responsible for linking existing quality-assurance networks to a global one to ensure collaboration. Although there is no decision point in the document, work on this issue clearly continues apace.

While GHTC will follow these agenda items closely, we will also keep an eye out for other late-breaking resolutions or developments and will post a follow-up blog after the EB with updates on the actual happenings!

Matt Robinson in GHTC's Policy & Advocacy Officer.

 

 


About the author

Matthew RobinsonGHTC

Matthew Robinson is a policy and advocacy officer at GHTC who leads the coalition's multilateral advocacy work.

Other Breakthroughs Blog posts you may like:
NIAID
January 24, 2016

Research Roundup: an Ebola vaccine, stillbirths, and antimicrobial R&D

Written by Kat Kelley / GHTC
Read time:
Photo: National Institute of Allergy and Infectious Diseases (NIAID) Gavi, the Vaccine Alliance, signed an advanced purchase commitment, pledging to spend US$5 million on an Ebola vaccine currently under development by pharmaceutical company Merck & Co. The vaccine candidate was tested on 4,000 people in Guinea last year, and the results were promising: despite all participants having close contact with at least one Ebola patient, none developed the disease more than ten days after vaccination (several days are required for a vaccine to confer protection). The vaccine candidate—VSV-EBOV—was developed and tested in partnership with the Canadian and US governments, however, without the urgency of an outbreak, public-sector support moving forward is limited. The agreement guarantees that there will be a market for the vaccine, assuring Merck & Co. that they can recover investments in advanced development and manufacturing. This move will also enable Gavi to establish a stockpile of the vaccine so that it can be rapidly deployed in future outbreaks. New research suggests that 2.6 million stillbirths occur each year, 420,000 of which are attributable to malaria or syphilis infections. These results underscore the need for testing and treatment of malaria and syphilis in pregnant women, particularly in endemic regions. Fortunately, there are low-cost interventions that could drastically reduce adverse pregnancy outcomes attributable to malaria and syphilis infections. The malaria parasite is able to reside in the placenta, even when undetectable in the mother’s blood, and thus, preventative treatment for malaria is critical. The antimalarial sulphadoxine-pyrimethamine, which costs a mere $0.20 per patient, is recommended for use in pregnant women in endemic areas. In east and southern Africa, an estimated 5 percent of pregnant women are infected with syphilis and in Tanzania, up to half of stillbirths are caused by syphilis. However, one dose of penicillin can cure both maternal and congenital syphilis and prevent stillbirth—at just $1.40 per person. While malaria- and syphilis-related stillbirths can be prevented with the scale-up of existing medicines, many more could be prevented with interventions that are not appropriate for low-resource settings, which is particularly concerning as 98 percent of stillbirths occur in low- and middle-income countries. Further, the cause of stillbirth is often unknown, according to the Global Alliance to Prevent Prematurity and Stillbirth, and additional research is needed to determine and address these causes. There is little incentive for pharmaceutical companies to invest in antimicrobial research and development (R&D): antibiotics are prescribed for short periods of time and competition among antibiotics keeps prices low. However, with the spread of drug resistance, the “[financial] value assigned to antibiotics and diagnostics often does not reflect the benefits they bring to society,” according to a declaration authored by 80 pharmaceutical and diagnostic companies and released at this year‘s World Economic Forum in Davos, Switzerland. The declaration calls on governments to work with the pharmaceutical industry to spur antimicrobial R&D, identifying innovative financing mechanisms, including prizes (a Market Entry Rewards initiative) and intellectual property–related incentives. In response, the companies pledge to invest in R&D for new antibiotics, as well as improved diagnostics to prevent the unnecessary use of antibiotics (i.e., for viral conditions).
International Vaccine Institute
January 18, 2016

Research Roundup: Vaccines for cholera and river blindness and an online platform for pooled procurement

Written by Kat Kelley / GHTC
Read time:
Last week, an oral cholera vaccine receivedWorld Health Organization (WHO) prequalification, a process of regulatory review which paves the way for procurement by United Nations agencies and international organizations. Up to 4.3 million cases and 142,000 deaths from cholera are reported annually, primarily in low- and middle-income countries, and the vaccine—Euvichol®—is 65 percent effective against the bacteria. Euvichol® was developed by GHTC member the International Vaccine Institute (IVI), and has been licensed to the Korean company Eubiologics, which plans to produce 6 million doses in 2016. The vaccine is a reformulated version of Shanchol™, which is licensed to Shantha Biotechnics in India, and was prequalified in 2011. According to the WHO, prequalification of Euvichol® could double the global supply of cholera vaccines. Euvichol® produced by EuBiologics. Photo: IVI Scientists have identified three compounds that could serve as the basis for a vaccine against onchocerciasis (river blindness). More than 17 million people globally are affected by river blindness, 70 percent of whom experience skin conditions, including itching and lesions, and 10 percent of whom develop eye conditions, leading to visual impairment. Without a vaccine, river blindness control programs use the antiparasitic drug ivermectin to treat the disease, however, ivermectin is not recommended for use in children under five. Additionally, in Central and Western Africa, where coinfection with Loa loa worms is common, use of ivermectin can lead to fatal brain inflammation. The team hopes to initiate safety and efficacy trials for a potential vaccine candidate by 2020 and 2025, respectively. The Global Fund to Fight AIDS, Tuberculosis and Malaria is launching an “e-marketplace” through which global health product procurers (i.e., governments and nongovernmental organizations) can purchase everything from drugs and diagnostics to condoms and cars. The e-marketplace will be an online platform utilizing the Global Fund’s pooled procurement mechanisms. Through this mechanism, the Global Fund negotiates with manufacturers and purchases large quantities of global health commodities; governments and other organizations are then able to purchase products directly from the Global Fund, reducing product and transaction costs. This approach also improves demand forecasting and ensures a sustainable supply of products. The launch of the e-marketplace will be phased: while in the first quarter of 2016, only bednets will be available, artemisinin combination malaria medicines, malaria and HIV and AIDS diagnostics, and antiretrovirals will be available by the end of the year. The e-marketplace will initially be limited to Global Fund grant recipients, and 10 to 20 countries are expected to utilize the platform in 2016. The Global Fund hopes to open the e-marketplace to more buyers in the future and eventually offer products that are not part of Global Fund agreements, enabling procurers to independently compare quotes from different manufacturers.